Prostate Cancer clinical trials in Massachusetts

53 actively recruiting prostate cancer trials at 10 sites across Massachusetts.

Data from ClinicalTrials.gov · last refreshed 2026-09-07

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Regeneron Pharmaceuticals funds and runs this clinical trial (NCT03972657). In 2024, Regeneron Pharmaceuticals reported paying the doctors leading the trial a total of $2,249,252 for research work on this study.

Who paid

Regeneron Pharmaceuticals, Inc. $2,249,252

Paid for research work on this trial

BILAL SIDDIQUI $843,045
EDWARD GELMANN(oncologist on CancerDrs) $282,711
BENEDITO CARNEIRO FILHO(oncologist on CancerDrs) $234,450
DAVID WISE(oncologist on CancerDrs) $232,180
CHE-KAI TSAO(oncologist on CancerDrs) $172,450

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

Brigham and Women's Hospital funds and runs this clinical trial (NCT06062745). In 2024, Brigham and Women's Hospital reported paying the doctors leading the trial a total of $135,274 for research work on this study.

Who paid

Blue Earth Diagnostics Limited $135,274

Paid for research work on this trial

HEATHER JACENE $135,274

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology

NCT ID: NCT05946213

Sites in Massachusetts:

Brigham and Women's Hospital — Boston, Massachusetts
Dana-Farber Cancer Institute — Boston, Massachusetts
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional — Milford, Massachusetts
Dana-Farber/Brigham and Women's Cancer Center at South Shore — South Weymouth, Massachusetts